2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€3.31M
Enterprise Value€4.85M
Total Cash (Recent Filing)€16.59M
Total Debt (Recent Filing)€2.19M
Price to Earnings (P/E)―
Beta-81.09
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low leverage (debt/equity ~0.03) reduces near-term solvency risk and gives management runway to fund clinical development. For a precommercial medtech, low debt preserves optionality for staged financing, partnerships, and execution over several quarters.
Proprietary IDOSE PDT PlatformThe IDOSE® platform's fiber-optic delivery with real-time monitoring enables precise interstitial PDT dosing. That technical differentiation can form a durable competitive edge, support clinical adoption, and create higher barriers to entry as trials and regulatory work progress.
Focused Initial Clinical TargetConcentrating on prostate cancer narrows R&D and regulatory scope, allowing clearer trial design and measurable endpoints. A focused indication can accelerate evidence generation, regulatory clarity, and targeted commercial planning over the coming months.
Bears Say
Negligible RevenueReported revenue is effectively zero, indicating no commercial sales traction. Without operational revenue, the company remains wholly dependent on financing to fund development and overhead, limiting ability to validate the business model or scale operations over the medium term.
Large And Worsening Net LossesNet losses widened materially to roughly -56m, reflecting increasing cost absorption without offsetting sales. Persistent large losses accelerate equity depletion and increase the probability of future financing rounds, raising dilution risk and constraining strategic flexibility.
Sustained Negative Operating And Free Cash FlowOperating cash flow and free cash flow are deeply negative and deteriorating, producing a material cash burn. Sustained negative cash flow requires external financing to reach clinical milestones, compresses runway, and limits the company's ability to invest in trials or commercialization without dilution.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €3.31M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is Aug 21, 2026 which is in 45 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on May 27, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.